VivoSeq
Other

Shock

13

Pipeline Programs↗

6

Active Trials↗

13

Companies Involved↗

Shock is an emerging landscape with 13 programs across 13 companies. The most active players are Orion Corporation, Orion Pharma, Amring, Pfizer. 10 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

11/100

Mech. Concentration

15/100

Completion Rate

88/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Orion Corporation, Orion Pharma logo

Orion Corporation, Orion Pharma

1 program

Phase 3A

Amring

1 program

ApprovedPfizer logo

Pfizer

1 program

ApprovedM

Milestone Pharmaceuticals Inc.

1 program

ApprovedM

McGuff Pharmaceuticals, Inc.

1 program

ApprovedV

Viatris Specialty LLC

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

22

clinical trials

Unknown status8 · 36%
Completed7 · 32%
Recruiting4 · 18%
Not yet recruiting2 · 9%
Withdrawn1 · 5%

Clinical Trials

Trial Activity

22 trials

Can Acupoint Low Intensity Shockwave Therapy Improve Bladder Voiding Efficiency
Recruiting·—·N/A·NCT06020963·100 enrolled
Registry of Patients in Shock Treated With Vasopressin
Recruiting·HHospital Universitario 12 de Octubre·N/A·NCT06422975·500 enrolled
Impact of Endothelial and Leukocyte Senescence in Circulatory Shock States
Recruiting·UUniversity Hospital, Strasbourg, France·N/A·NCT03559569·520 enrolled
Multi-center, Randomized, Placebo-controlled, Double-blind Phase 1b/2a Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Invobenitug Also Knows as Procizumab (PCZ; AK1967) in Patients With Cardiogenic Shock and Elevated Circulating Dipeptidyl Peptidase 3 (cDPP3) Concentrations
Recruiting·44TEEN4 Pharmaceuticals GmbH·Preclinical·NCT06832722·90 enrolled
Tissue Perfusion Pressure for Predicting Fluid Responsiveness in Patients With Shock: A Prospective Observational Study
Not yet recruiting·JJingyuan,Xu·N/A·NCT07670390·34 enrolled
Angiotensin II for Post Cardiac Surgery Vasoplegia (ANGII_V)
Not yet recruiting·MMethodist Healthcare System of San Antonio·Approved·NCT07671365·329 enrolled
Dopamine and Norepinephrine in Shock Patients
Completed·SSepsis Occurrence in Acutely Ill Patients·Phase 3·NCT00314704·1,679 enrolled
Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)
Completed·SShockwave Medical, Inc.·N/A·NCT02923193·306 enrolled
Investigations of New Markers in Patients With Shock
Completed·AAssistance Publique Hopitaux De Marseille·N/A·NCT00919685·50 enrolled
The Effect of SSRIs on Threat of Shock Potentiated Neural Circuitry
Completed·UUCLH/UCL Joint Research Office·N/A·NCT07074652·145 enrolled
Study of the Expression of Heat Shock Proteins in Populations of B Lymphocytes in Human Tonsils
Completed·—·N/A·NCT02859090·5 enrolled
Comparaison de Mesure de débit Cardiaque Entre système Clearsight® et Thermodilution Transpulmonaire.
Completed·UUniversity Hospital, Brest·N/A·NCT02728791·42 enrolled
Determinants of Muscle - Skin Distance at the Injection Site in Patients With an Indication for the Use of Epinephrine Auto- Injector Pens
Completed·CCentre Hospitalier Régional Metz-Thionville·Preclinical·NCT02886468·107 enrolled
Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy
Withdrawn·AAlbert Einstein Healthcare Network·Phase 3·NCT01560091
the Effect of Oral Vasopressors for Liberation From IV Vasopressors in Spinal Shock
Unknown status·AAhmed talaat ahmed aly·Phase 2·NCT04586790·90 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)